Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

ABSTRACT:

Background

The duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Objective

To determine if prior endocrine therapy duration is an indicator of abiraterone acetate (AA) sensitivity.

Design, setting, and participants

Post-hoc exploratory analysis of randomised phase 3 studies examining post-docetaxel (COU-AA-301) or chemotherapy-naïve mCRPC (COU-AA-302) patients receiving AA. The treatment effect on overall survival (OS), radiographic progression-free survival (rPFS), and prostate-specific antigen (PSA) response analysed by quartile duration of prior gonadotropin-releasing hormone agonists (GnRHa) or androgen receptor (AR) antagonist.

Intervention

Patients wer

SUBMITTER: Bellmunt J 

PROVIDER: S-EPMC5465643 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature